home / stock / galt / galt quote
Last: | $2.39 |
---|---|
Change Percent: | 1.24% |
Open: | $2.38 |
Close: | $2.39 |
High: | $2.4297 |
Low: | $2.3 |
Volume: | 57,667 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.39 | $2.38 | $2.39 | $2.4297 | $2.3 | 57,667 | 03-28-2024 |
$2.41 | $2.36 | $2.41 | $2.42 | $2.31 | 82,953 | 03-27-2024 |
$2.37 | $2.36 | $2.37 | $2.3998 | $2.2725 | 75,063 | 03-26-2024 |
$2.33 | $2.44 | $2.33 | $2.4799 | $2.305 | 134,904 | 03-25-2024 |
$2.44 | $2.47 | $2.44 | $2.4799 | $2.32 | 155,960 | 03-22-2024 |
$2.44 | $2.2 | $2.44 | $2.45 | $2.19 | 290,939 | 03-21-2024 |
$2.2 | $2.08 | $2.2 | $2.2 | $2.0625 | 109,413 | 03-20-2024 |
$2.1 | $2.17 | $2.1 | $2.18 | $2.08 | 51,313 | 03-19-2024 |
$2.14 | $2.04 | $2.14 | $2.17 | $2.01 | 151,910 | 03-18-2024 |
$2.06 | $2.02 | $2.06 | $2.08 | $1.9702 | 165,790 | 03-15-2024 |
$1.98 | $1.98 | $1.98 | $1.98 | $1.93 | 40,110 | 03-14-2024 |
$1.98 | $1.97 | $1.98 | $2.025 | $1.9276 | 34,749 | 03-13-2024 |
$1.97 | $2 | $1.97 | $2.09 | $1.91 | 100,845 | 03-12-2024 |
$2.01 | $2.03 | $2.01 | $2.07 | $1.99 | 46,689 | 03-11-2024 |
$2.04 | $2.1 | $2.04 | $2.1 | $1.99 | 45,038 | 03-08-2024 |
$2.09 | $2.07 | $2.09 | $2.09 | $1.98 | 106,763 | 03-07-2024 |
$2.08 | $2.08 | $2.08 | $2.0969 | $2.02 | 137,121 | 03-06-2024 |
$2.06 | $1.97 | $2.06 | $2.06 | $1.97 | 98,466 | 03-05-2024 |
$1.99 | $1.97 | $1.99 | $2.02 | $1.93 | 45,666 | 03-04-2024 |
$1.93 | $1.98 | $1.93 | $2.02 | $1.895 | 123,604 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Galectin Therapeutics Inc. Company Name:
GALT Stock Symbol:
NASDAQ Market:
Galectin Therapeutics Inc. Website:
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target g...
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost tw...
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are in...